The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)

Abstract

The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials.